Patents for A61P 35 - Antineoplastic agents (221,099)
04/2009
04/30/2009WO2009055074A2 Erbb2 binding proteins and use thereof
04/30/2009WO2009055053A2 Diarylhydantoin compounds as androgen receptor modulators
04/30/2009WO2009054970A1 Mesylate salt of an ikk inhibitor
04/30/2009WO2009054935A1 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
04/30/2009WO2009054864A1 Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
04/30/2009WO2009054747A1 Anti-metastatic agent
04/30/2009WO2009054558A1 A method for diagnosing disease using adenovirus harboring trans-splicing ribozyme by molecular imaging
04/30/2009WO2009054483A1 Drug containing salusin-β
04/30/2009WO2009054471A1 Immune response inducer
04/30/2009WO2009054470A1 Immune response inducer and use thereof
04/30/2009WO2009054454A1 Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient
04/30/2009WO2009054332A1 Pyridone-substituted-dihydropyrazolopyrimidinone derivative
04/30/2009WO2009054001A1 A pharmaceutical composition and a process thereof
04/30/2009WO2009053982A1 Constructs containing multiple expression cassettes for cancer therapy
04/30/2009WO2009053804A2 Idarubicin for the treatment of lymphoma in a dog
04/30/2009WO2009053716A1 Purine derivatives useful as pi3 kinase inhibitors
04/30/2009WO2009053715A1 Thienopyrimidiene derivatives as pi3k inhibitors
04/30/2009WO2009053694A1 Therapeutic oxy-phenyl-aryl compounds and their use
04/30/2009WO2009053654A2 Gemcitabine phosphoester prodrugs as anticancer agents
04/30/2009WO2009053644A2 Use of lanthanide-based nanoparticles as radiosensitizing agents
04/30/2009WO2009053628A2 Novel compounds, preparation and uses thereof
04/30/2009WO2009053467A2 The use of a non-glycanated polypeptide for treating a cancer
04/30/2009WO2009053445A2 Polymorphic forms of ibandronate sodium and processes for preparation thereof
04/30/2009WO2009053373A1 Quinolinone derivatives as parp inhibitors
04/30/2009WO2009053109A1 Antigen-specific t-cell preparations from bone marrow
04/30/2009WO2009053102A1 Novel imidazole derivatives
04/30/2009WO2009053101A1 Novel imidazole derivatives
04/30/2009WO2009053064A1 Sdf-1-based glycosaminoglycan antagonists and methods of using same
04/30/2009WO2009053038A2 Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor
04/30/2009WO2009052711A1 New compounds isolated from extract of antrodia camphorata
04/30/2009WO2009052617A1 Treatment regime for proliferative disorders
04/30/2009WO2009052561A1 Compositions and methods for manipulating an immune response
04/30/2009WO2009033733A3 Use of apeptide as a therapeutic agent
04/30/2009WO2009027644A8 Compositions for the treatment of neoplastic diseases
04/30/2009WO2009022988A3 Vhz for diagnosis and treatment of cancer
04/30/2009WO2009021169A3 (7h-pyrr0l0 [2, 3-d] pyrimidin-4-yl) -piperazines as kinase inhibitors for the treatment of cancer and inflammation
04/30/2009WO2009019312A3 Anti cd37 antibodies
04/30/2009WO2009013619A3 The ed-a antigen of fibrinogen is associated with the neovas culature of tumor metastases
04/30/2009WO2009011910A3 Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
04/30/2009WO2009011871A3 Thiadiazole modulators of pkb
04/30/2009WO2008155387A3 Anti-igf antibodies that bind to igf-1 and igf-2 but not to insulin
04/30/2009WO2008140553A4 Mapk/erk kinase inhibitors
04/30/2009WO2008140421A3 Heterocycloalkyl substituted pyrimidine derivatives
04/30/2009WO2008140420A3 Pyrimidine derivatives
04/30/2009WO2008140419A3 Pyridyl substituted pyrimidine derivatives
04/30/2009WO2008138889A3 3, 6-disubstituted-imidazo [1, 2-b] pyridazines and 3, 5-disubstituted pyrazolo[1, 5-a] pyrimidines as phosphatidylinositol-3-kinase inhibitors
04/30/2009WO2008127594A3 Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
04/30/2009WO2008126123A3 Water-soluble coronene derivatives active as inhibitors of telomerase
04/30/2009WO2008109498A4 Nucleic acid compounds for inhibiting hdac gene expression and uses thereof
04/30/2009WO2008094969A3 Combination therapy with angiogenesis inhibitors
04/30/2009WO2008094834A3 Multi-functional drug carriers
04/30/2009WO2008011710A8 Cytotoxicity mediation of cells evidencing surface expression of cd63
04/30/2009WO2007059099A3 Boroproline combination therapy for cancer
04/30/2009WO2007058850A3 Inhibitors of akt activity
04/30/2009WO2007016254A3 Antineoplastic activities of ellipticine and its derivatives
04/30/2009WO2007014327A3 Small compounds that correct protein misfolding and uses thereof
04/30/2009WO2005010169A3 High throughput or capillary-based screening for a bioactivity or biomolecule
04/30/2009WO2004092199A3 Method for identifying modulators of g protein coupled receptor signaling
04/30/2009US20090111870 Angelicae Sinensis Extracts Useful for Treatment of Cancers
04/30/2009US20090111869 Benzoquinone ansamycins
04/30/2009US20090111862 Compound
04/30/2009US20090111860 Sulfonamide compounds useful as adg receptor modulators
04/30/2009US20090111859 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes
04/30/2009US20090111845 Treating a cancer or malignant tumor using the crystalline camptothecin ester hydrates; nontoxic
04/30/2009US20090111836 Angular Pyranocoumarins, Process for Preparation and Uses Thereof
04/30/2009US20090111828 L-alanine derivatives
04/30/2009US20090111816 Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
04/30/2009US20090111802 Cyclocarbamate derivatives as progesterone receptor modulators
04/30/2009US20090111799 Anti-infective agents against intracellular pathogens
04/30/2009US20090111784 Medication against breast cancer and related diseases
04/30/2009US20090111779 Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
04/30/2009US20090111772 Formulation of quinazoline based egfr inhibitors containing a zinc binding moiety
04/30/2009US20090111765 Compositions and methods for immunostimulatory rna oligonucleotides
04/30/2009US20090111762 Method of diagnosing and treating cancer using b-catenin splice variants
04/30/2009US20090111756 Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus
04/30/2009US20090111738 Fibronectin polypeptides and methods of use
04/30/2009US20090110757 Methods for modulating eicosanoid metabolism
04/30/2009US20090110753 Enzyme-cleavable prodrug compounds
04/30/2009US20090110746 New class of therapeutics that enhance small modecule diffusion
04/30/2009US20090110718 Derivatives of tiacumicin B as anti-cancer agents
04/30/2009US20090110696 Mycobacterial SecA2 Mutants
04/30/2009US20090110687 Compositions and methods related to tim 3, a th1-specific cell surface molecule
04/30/2009US20090110681 Anti-M-CSF Antibody Compositions
04/30/2009US20090110678 Receptor antagonists for treatment of metastatic bone cancer
04/30/2009US20090110677 Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
04/30/2009US20090110676 BAFF, Inhibitors Thereof and Their Use in the Modulation of B-Cell Response and Treatment of Autoimmune Disorders
04/30/2009US20090110666 Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours
04/30/2009US20090110665 Reovirus for the treatment of neoplasia
04/30/2009US20090110659 Immunoglobulin specific to eotaxin for use in diagnosis, prevention and treatment of infections, autoimmune, inflammatory and allergic disorders; chemotactic cytokines designated human eotaxins; selectively modulate leukocyte function
04/30/2009US20090110644 Polymer nanoparticles coated by magnetic metal oxide and uses thereof
04/30/2009DE102007047737A1 Piperidin- und Piperazinderivate Piperidine and piperazine derivatives
04/30/2009DE10128250B4 Neue Glykolipidderivate, Verfahren zu deren Herstellung und diese enthaltende Mittel Glykolipidderivate new, processes for their preparation and compositions comprising them
04/30/2009CA2704052A1 Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
04/30/2009CA2703774A1 Constructs containing multiple expression cassettes for cancer therapy
04/30/2009CA2703653A1 Pyridine and pyrazine derivatives -083
04/30/2009CA2703635A1 Diarylhydantoin compounds as androgen receptor modulators
04/30/2009CA2703489A1 Pyridone-substituted-dihydropyrazolopyrimidinone derivative
04/30/2009CA2703477A1 Tropane compounds
04/30/2009CA2703350A1 Immune response inducer
04/30/2009CA2703184A1 Inhibition of urokinase-type plasminogen activator (upa) activity